EP1198243A2 - Use of cpg as an adjuvant for malaria vaccine - Google Patents

Use of cpg as an adjuvant for malaria vaccine

Info

Publication number
EP1198243A2
EP1198243A2 EP00945810A EP00945810A EP1198243A2 EP 1198243 A2 EP1198243 A2 EP 1198243A2 EP 00945810 A EP00945810 A EP 00945810A EP 00945810 A EP00945810 A EP 00945810A EP 1198243 A2 EP1198243 A2 EP 1198243A2
Authority
EP
European Patent Office
Prior art keywords
vaccine
cpg
rts
oligonucleotide
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00945810A
Other languages
German (de)
French (fr)
Inventor
Joseph Cohen
Nathalie Garcon
Gerald Voss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of EP1198243A2 publication Critical patent/EP1198243A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a novel vaccine formulations and their use in medicine, particularly in the prevention of malaria infections.
  • the present invention is concerned with a CpG oligonucleotide and a malarial antigen.
  • Malaria is one of the world's major health problems with 2 to 4 million people dying from the disease each year.
  • One of the most acute forms of the disease is caused by the protozoan parasite, Plasmodium falciparum which is responsible for most of the mortality attributable to Malaria.
  • the life cycle of P. falciparum is complex, requiring two hosts, man and mosquito for completion.
  • the infection of man is initiated by the inoculation of sporozoites in the saliva of an infected mosquito.
  • the sporozoites migrate to the liver and there infect hepatocytes where they differentiate, via the exoerythrocytic intracellular stage, into the merozoite stage which infects red blood cells (RBC) to initiate cyclical replication in the asexual blood stage.
  • RBC red blood cells
  • the cycle is completed by the differentiation of a number of merozoites in the RBC into sexual stage gametocytes which are ingested by the mosquito, where they develop through a series of stages in the midgut to produce sporozoites which migrate to the salivary gland.
  • the sporozoite stage of P. falciparum has been identified as a potential target of a malaria vaccine.
  • the major surface protein of the sporozoite is known as circumsporozoite protein (CS Protein).
  • This protein from strain 7G8 has been cloned, expressed and sequenced (Dame et al Science 225 (1984) p593).
  • the protein from strain 7G8 is characterised by having a central immunodominant repeat region comprising a tetrapeptide Asn-Ala-Asn-Pro repeated 37 times but interspersed with four minor repeats Asn-Val- Asp-Pro. In other strains the number of major and minor repeats vary as well as their relative position.
  • This central portion is flanked by an N and C terminal portion composed of non-repetitive amino acid sequences designated as the repeatless portion of the CS protein. It has been shown that irradiated sporozoites can provide significant protection against experimental human malaria (Am. J. Trop. Med. Hyg. 24: 297-402, 1975). However, production difficulties makes the use of irradiated sporozoite impractical from the point of view of producing a vaccine.
  • the present invention provides a new, improved malaria vaccines which not only produces a humoral response, but also a cellular immune response.
  • the antigen induces the production of neutralising antibodies against the immunodominant repeat.
  • the antigen should also elicit effector T cell mediated immune responses of the CD4 + and CD8 + cytotoxic T lymphocyte (CTL) type and of the delayed type hypersensitivity type and also, preferably be able to induce T helper (TH) memory cells.
  • CTL cytotoxic T lymphocyte
  • TH T helper
  • WO 93 / 10152 provides a hybrid protein comprising substantially all the C-terminal portion of the CS protein, four or more tandom repeats of the immunodominant region, and the Surface antigen from Hepatitis B virus (HBsAg).
  • the hybrid protein comprises a sequence which contains at least 160 amino acids which is substantially homologous to the C-terminal portion of the CS protein.
  • the CS protein may be ⁇ evoid of the last 12 amino-acids from the C terminal.
  • a protein which comprises a portion of the CS protein of P. falciparum substantially as corresponding to amino acids 210-398 of P. falciparum 7G8 fused in frame via a linear linker to the N-terminal of HBsAg.
  • the linker may comprise a portion of preS2 from HBsAg.
  • RTS RTS,S
  • This hybrid consists of:
  • a methionine-residue encoded by nucleotides 1059 to 1061, derived from the Saccharomyces cerevisiae TDH3 gene sequence. (Musti A.M. et al Gene 1983 25 133-143).
  • Met Ala Pro Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
  • RTS* or RTS*,S
  • RTS* or RTS*,S
  • RTS* comprises:
  • TDH3 gene sequence (see Musti et al, loc cit).
  • Trap (or TRAP) from P. falciparum.
  • An apparent homologue of Trap is described in WO92/11868 and relates to an antigen called SSP2 from P. yeolii.
  • International patent application WO 98/ 05355 describes, inter alia, a malaria vaccine based on a combination of Trap and RTS,S.
  • Immunomodulatory oligonucleotides contain unmethylated CpG dinucleotides
  • CpG CpG
  • cytosine-guanosine dinucleotide motifs present in DNA.
  • synthetic oligonucleotides derived from BCG gene sequences were shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo).
  • the authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity.
  • the central role of the CG motif in i munostimulation was later elucidated in a publication by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA.
  • CG pyrimidine pyrimidine and where the CG motif is not methylated.
  • a palindromic sequence is present.
  • the presence of one or more of these immunostimulatory sequence containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon ⁇ and have cytolytic activity) and macrophages (Wooldrige et al Vol 89 (no. 8), 1977).
  • CpG oligonucleotide and a malaria antigen.
  • Vaccine preparation is generally described in Vaccine Design - The subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology Vol. 6 Plenum Press 1995. Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.
  • the preferred oligonucleotides preferably contain two or more CpG motifs separated by six or more nucleotides.
  • the oligonucleotides of the present invention are typically deoxynucleotides.
  • the intemucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorodithioate bond, although phosphodiester and other intemucleotide bonds are within the scope of the invention including oligonucleotides with mixed intemucleotide linkages.
  • the sequences preferably contain all phosphorodithioate modified intemucleotide linkages.
  • Preferred oligonucleotides have the following sequences:
  • a + in the Thio column indicates the presence of a thioate modification.
  • 'Mix' indicates a mixture of thioate modification and sequence without thioate modification (the asterisks indicate the linkages with a thioate modification).
  • a - in the Thio column indicates absence of a thioate modification.
  • a + in the CpG column indicates a the presence of a CpG motif and a - in the CpG column indicates absence of a CpG motif.
  • WD 1005 contains a GpC rather than a CpG motif, thus it is marked with a - in the CpG column of the table.
  • WD 1007 contains a palindromic motif (GACGTC) as well as other non-palindromic CpG sequences. This is also within the scope of a CpG oligonucleotide as the term is used in the present application.
  • oligonucleotides utilised in the present invention may be synthesized by any method known in the art (eg EP 0 468 520). Conveniently, such oligonucleotides may be synthesized utilising an automated synthesizer. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in US patent 5,666,153, US patent 5,278,302 and WO95/26204.
  • each vaccine does is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, preferably 2-100 ⁇ g, most preferably 5-50 ⁇ g. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.
  • a method for the prevention or amelioration of plasmodium infection in a patient comprising administering an effective amount of either a malaria antigen and a CpG oligonucleotide (as hereinabove defined) or an effective amount of the CpG oligonucleotide followed after a suitable time by an effective amount of a malaria antigen.
  • kits comprising effective amounts of a CpG oligonucleotide- containing formulation for use as a priming formulation for pre-administration to human patients and a malaria antigen for injection at some suitable time later, as described hereinabove.
  • Preferred CpG oligonucleotides are those indicated in the table hereinabove.
  • the CpG will be present in the range 10 ⁇ g per dose to 1000 ⁇ g, preferably 10-100 ⁇ g, especially 25-75 ⁇ g, for example 50 ⁇ g per dose.
  • the vaccine used in the present invention may comprise a carrier such as an aluminium salt, eg aluminium hydroxide [Al(OH)3], aluminium phosphate or aluminium phosphate sulfate (alum), or a non-toxic oil in water emulsion or a mixture thereof.
  • a carrier such as an aluminium salt, eg aluminium hydroxide [Al(OH)3], aluminium phosphate or aluminium phosphate sulfate (alum), or a non-toxic oil in water emulsion or a mixture thereof.
  • an aluminium salt preferably aluminium hydroxide
  • it is generally present in the range of 50 to 100 ⁇ g, preferably 100 to 500 ⁇ g per dose.
  • Non-toxic oil in water emulsions preferably contain a non-toxic oil, eg squalene and an emulsifier such as (polysorbitan monoleate) Tween 80, in an aqueous carrier such as phosphate buffered saline.
  • a non-toxic oil eg squalene and an emulsifier such as (polysorbitan monoleate) Tween 80
  • an aqueous carrier such as phosphate buffered saline.
  • the vaccine used in the present invention may comprise an additional adjuvant, preferably a saponin adjuvant such as QS21 as described for example in WO 9517210, optionally in the presence of a sterol, such as cholesterol as described for example in PCT/EP96/01464.
  • the vaccine of the invention may also comprise monophosphoryl lipid A and derivatives thereof known in the art.
  • a preferred derivative is 3 de-O-acylated monophosphoryl lipid A, described in British Patent No. 2220211.
  • vaccine formulations of the present invention may additionally comprise other pharmaceutical excipients or immunostimulants.
  • the vaccine formulation additionally comprises an aluminium salt, preferably aluminium hydroxide.
  • CTL cytotoxic T lymphocyte
  • Formulations were prepared 3 days before each injection. All incubations were carried out at room temperature with agitation.
  • CpG/alum group 1 (SOO ⁇ l/dose) RTS, S (8.7 ⁇ g) and gpl20 (8.7 ⁇ g) were adsorbed on 100 ⁇ g of Al(OH) 3 or AlPO 4 for 1 hour
  • the formulation was buffered with a 10-fold concentrated PO 4 /NaCl pH 6.8 solution before addition of lOO ⁇ g of CpG (WD 1001). After 15 min, 50 ⁇ g/ml of fhiomersal was added as preservative.
  • RTS,S (8.7 ⁇ g) and Gpl20(8.7 ⁇ g) were diluted in PBS pH 6.8 before addition of lOO ⁇ g of CpG (WDIOOI). After 5 min, 50 ⁇ g/ml of thiomersal was added as preservative.
  • mice Nine Balb/C mice per group received into the hind footpads 100 ⁇ l vaccine twice at a two-week-interval. Two weeks later spleen cells were harvested and used to determine the induction of HBsAg-specific CTL.
  • CTL analysis cells were cultured for 7 days in 6-well plates in the presence of 10 ⁇ g per ml of synthetic peptide pCMI003 corresponding to an HBsAg CTL epitope (Schirrnbeck et al. , 1995). At the end of the culture period cells were assessed in duplicate for HBsAg-specific cytolytic activity in standard [ 51 Cr] -release assays using control and S-transfected P815 cells.
  • Formulations were prepared one day before each injection. All incubations were carried out at room temperature with agitation.
  • RTS,S (50 ⁇ g) was adsorbed on 500 ⁇ g of Al(OH) 3 for 1 hour The formulation was buffered with a 10-fold concentrated PO 4 /NaCl pH 6.8 solution before addition of 500 ⁇ g of CpG (WDIOOI). After 15 min, 50 ⁇ g/ml of thiomersal was added as preservative.
  • RTS,S (50 ⁇ g) was diluted in PO 4 /NaCl buffer pH 6.8 before addition of 500 ⁇ g of CpG WDIOOI . After 15 min, 50 ⁇ g/ml of thiomersal was added as preservative.
  • rhesus monkeys (Macaca mulatto.) per group were immunized twice intramuscularly with 500 ⁇ l of vaccine at a four- week-interval.
  • Sera and peripheral blood mononuclear cells were taken at several occasions.
  • HBsAg-specific antibodies in monkey sera were determined in a radio immuno assay (RIA, Abbott) according to the manufacturer's instructions.
  • Figure 1 CTL activity of spleen cells from immunized mice. Effector cell activity was assessed by examining 51 Cr release of P815 cells (open circles) or s-transfected P815 cells (closed circles).
  • Figure 2 HBsAg-specific antibody responses in immunized rhesus monkeys. Specific antibodies were evaluated using a commercially available RIA. Individual values from multiple time points for each animal are shown in the table, and group averages are shown in the table and as a graphic.
  • FIG. 3 RTS,S-specif ⁇ c lymphoproliferation in immunized rhesus monkeys 6 days post second immunization. PBMC were stimulated with RTS,S antigen and lymphoproliferative responses were measured by 3 H-thymidine incorporation. Results are expressed in cpm and as SI.

Abstract

A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of P. falciparum fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the malaria antigen.

Description

VACCINES
The present invention relates to a novel vaccine formulations and their use in medicine, particularly in the prevention of malaria infections. In particular the present invention is concerned with a CpG oligonucleotide and a malarial antigen.
Malaria, is one of the world's major health problems with 2 to 4 million people dying from the disease each year. One of the most acute forms of the disease is caused by the protozoan parasite, Plasmodium falciparum which is responsible for most of the mortality attributable to Malaria.
The life cycle of P. falciparum is complex, requiring two hosts, man and mosquito for completion. The infection of man is initiated by the inoculation of sporozoites in the saliva of an infected mosquito. The sporozoites migrate to the liver and there infect hepatocytes where they differentiate, via the exoerythrocytic intracellular stage, into the merozoite stage which infects red blood cells (RBC) to initiate cyclical replication in the asexual blood stage. The cycle is completed by the differentiation of a number of merozoites in the RBC into sexual stage gametocytes which are ingested by the mosquito, where they develop through a series of stages in the midgut to produce sporozoites which migrate to the salivary gland.
The sporozoite stage of P. falciparum has been identified as a potential target of a malaria vaccine. The major surface protein of the sporozoite is known as circumsporozoite protein (CS Protein). This protein from strain 7G8 has been cloned, expressed and sequenced (Dame et al Science 225 (1984) p593). The protein from strain 7G8 is characterised by having a central immunodominant repeat region comprising a tetrapeptide Asn-Ala-Asn-Pro repeated 37 times but interspersed with four minor repeats Asn-Val- Asp-Pro. In other strains the number of major and minor repeats vary as well as their relative position. This central portion is flanked by an N and C terminal portion composed of non-repetitive amino acid sequences designated as the repeatless portion of the CS protein. It has been shown that irradiated sporozoites can provide significant protection against experimental human malaria (Am. J. Trop. Med. Hyg. 24: 297-402, 1975). However, production difficulties makes the use of irradiated sporozoite impractical from the point of view of producing a vaccine.
Several groups have proposed subunit vaccines based on the circumsporozoite protein. Two of these vaccines have undergone clinical testing; one is a synthetic peptide, the other is a recombinant protein (Ballou et al Lancet: i 1277 (1987) and Herrington et_al Nature 328:257 (1987).
These vaccines were successful in stimulating an anti-sporozoite response. Nonetheless, the magnitude of the response was disappointing, with some vaccinees not making a response at all. Furthermore, the absence of "boosting" of antibody levels on subsequent injections and results of in vitro lymphocyte proliferation assays suggested that T-cells of most of these volunteers did not recognise the irnmuno-dominant repeat. Nonetheless, one vaccinee in each study did not develop parasitemia.
The present invention provides a new, improved malaria vaccines which not only produces a humoral response, but also a cellular immune response. Preferably the antigen induces the production of neutralising antibodies against the immunodominant repeat. Most preferably, the antigen should also elicit effector T cell mediated immune responses of the CD4+ and CD8+ cytotoxic T lymphocyte (CTL) type and of the delayed type hypersensitivity type and also, preferably be able to induce T helper (TH) memory cells.
International patent application No. WO 93 / 10152 (SmithKline Beecham Biologicals s.a) provides a hybrid protein comprising substantially all the C-terminal portion of the CS protein, four or more tandom repeats of the immunodominant region, and the Surface antigen from Hepatitis B virus (HBsAg). Preferably the hybrid protein comprises a sequence which contains at least 160 amino acids which is substantially homologous to the C-terminal portion of the CS protein. The CS protein may be αevoid of the last 12 amino-acids from the C terminal.
In particular there is provided a protein which comprises a portion of the CS protein of P. falciparum substantially as corresponding to amino acids 210-398 of P. falciparum 7G8 fused in frame via a linear linker to the N-terminal of HBsAg. The linker may comprise a portion of preS2 from HBsAg.
A particularly preferred embodiment is the hybrid protein designated RTS (or RTS,S). This hybrid consists of:
• A methionine-residue, encoded by nucleotides 1059 to 1061, derived from the Saccharomyces cerevisiae TDH3 gene sequence. (Musti A.M. et al Gene 1983 25 133-143).
• Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
• A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 210 to 398 of the circumsporozoite protein (CSP) of Plasmodium falciparum strain 7G8 (Dame et al supra).
• An amino acid (Arg) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
• Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (9).
• A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype). In an alternative embodiment there is provided a hybrid protein designated RTS* (or RTS*,S), which was generated using the CSP gene sequence from P. falciparum NF54 (Mol. Biochem Parisitol. 35 : 185-190, 1989) and comprises substantially all of the region 207 to 395 of the CS protein from P falciparum NF54.
In particular RTS* comprises:
• A Methionine, encoded by nucleotides 1059 to 1061, derived from the
TDH3 gene sequence (see Musti et al, loc cit)..
• Three arnino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
• A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 207 to 395 of the circumsporozoite protein (CSP) of Plasmodium falciparum strain NF54 (Mol. Biochem. Parasitol, 35: 185- 190, 1989).
• An amino acid (Gly) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
• Four arnino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (Nature 280:815-819, 1979).
• A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype) (Nature 280:815- 819, 1979)
International patent application no. WO 90/01496 describe an antigen known as
Trap (or TRAP) from P. falciparum. An apparent homologue of Trap is described in WO92/11868 and relates to an antigen called SSP2 from P. yeolii. International patent application WO 98/ 05355 describes, inter alia, a malaria vaccine based on a combination of Trap and RTS,S.
Immunomodulatory oligonucleotides contain unmethylated CpG dinucleotides
("CpG") and are known (WO 96/02555, EP 468520). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it was observed that the DNA fraction of BCG could exert an anti-tumour effect. In further studies, synthetic oligonucleotides derived from BCG gene sequences were shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity. The central role of the CG motif in i munostimulation was later elucidated in a publication by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA.
It is currently believed that this evolutionary difference allows the vertebrate immune system to detect the presence of bacterial DNA (as occurring during an infection) leading consequently to the stimulation of the immune system. The immunostimulatory sequence as defined by Krieg is:
Purine Purine CG pyrimidine pyrimidine and where the CG motif is not methylated. In certain combinations of the six nucleotides a palindromic sequence is present. Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same oligonucleotide. The presence of one or more of these immunostimulatory sequence containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon γ and have cytolytic activity) and macrophages (Wooldrige et al Vol 89 (no. 8), 1977). Although other unmethylated CpG containing sequences not having this consensus sequence have now been shown to be immunomodulatory. The present invention provides an improved vaccine formulation comprising a CpG oligonucleotide and a malaria antigen. In particular, RTS,S or RTS,S* or Trap or i munologically equivalent derivatives thereof.
Vaccine preparation is generally described in Vaccine Design - The subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology Vol. 6 Plenum Press 1995. Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.
The preferred oligonucleotides preferably contain two or more CpG motifs separated by six or more nucleotides. The oligonucleotides of the present invention are typically deoxynucleotides. In a preferred embodiment the intemucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorodithioate bond, although phosphodiester and other intemucleotide bonds are within the scope of the invention including oligonucleotides with mixed intemucleotide linkages. The sequences preferably contain all phosphorodithioate modified intemucleotide linkages. Preferred oligonucleotides have the following sequences:
* alternatively referred to as WD001-WD007 In the above table a + in the Thio column indicates the presence of a thioate modification. 'Mix' indicates a mixture of thioate modification and sequence without thioate modification (the asterisks indicate the linkages with a thioate modification). A - in the Thio column indicates absence of a thioate modification. A + in the CpG column indicates a the presence of a CpG motif and a - in the CpG column indicates absence of a CpG motif. For example WD 1005 contains a GpC rather than a CpG motif, thus it is marked with a - in the CpG column of the table. WD 1007 contains a palindromic motif (GACGTC) as well as other non-palindromic CpG sequences. This is also within the scope of a CpG oligonucleotide as the term is used in the present application.
The oligonucleotides utilised in the present invention may be synthesized by any method known in the art (eg EP 0 468 520). Conveniently, such oligonucleotides may be synthesized utilising an automated synthesizer. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in US patent 5,666,153, US patent 5,278,302 and WO95/26204.
The amount of protein in each vaccine does is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 μg of protein, preferably 2-100 μg, most preferably 5-50 μg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.
It is also possible to pre-administer the CpG oligonucleotide as a 'priming formulation' shortly prior to vaccination with the malaria antigen, for example 1 day before. Accordingly, according to another aspect of the invention, there is provided a method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of either a malaria antigen and a CpG oligonucleotide (as hereinabove defined) or an effective amount of the CpG oligonucleotide followed after a suitable time by an effective amount of a malaria antigen.
There is also provided a kit comprising effective amounts of a CpG oligonucleotide- containing formulation for use as a priming formulation for pre-administration to human patients and a malaria antigen for injection at some suitable time later, as described hereinabove.
Preferred CpG oligonucleotides are those indicated in the table hereinabove.
Suitably the CpG will be present in the range 10 μg per dose to 1000 μg, preferably 10-100μg, especially 25-75 μg, for example 50 μg per dose.
Suitably the vaccine used in the present invention may comprise a carrier such as an aluminium salt, eg aluminium hydroxide [Al(OH)3], aluminium phosphate or aluminium phosphate sulfate (alum), or a non-toxic oil in water emulsion or a mixture thereof.
If an aluminium salt (preferably aluminium hydroxide) is used as a carrier it is generally present in the range of 50 to 100 μg, preferably 100 to 500 μg per dose.
Non-toxic oil in water emulsions preferably contain a non-toxic oil, eg squalene and an emulsifier such as (polysorbitan monoleate) Tween 80, in an aqueous carrier such as phosphate buffered saline.
If desired the vaccine used in the present invention may comprise an additional adjuvant, preferably a saponin adjuvant such as QS21 as described for example in WO 9517210, optionally in the presence of a sterol, such as cholesterol as described for example in PCT/EP96/01464. The vaccine of the invention may also comprise monophosphoryl lipid A and derivatives thereof known in the art. A preferred derivative is 3 de-O-acylated monophosphoryl lipid A, described in British Patent No. 2220211.
Accordingly vaccine formulations of the present invention may additionally comprise other pharmaceutical excipients or immunostimulants. In a preferred embodiment the vaccine formulation additionally comprises an aluminium salt, preferably aluminium hydroxide.
The present invention will now be described with reference to the following examples:
LMMUNOGENICITY STUDIES USING RTS,S FORMULATED WITH CPG OR CPG/ ALUM
Evaluation of CpG and CpG/alum in mice
Experiment outline
An immunogenicity study was conducted to evaluate the ability of CpG to serve as an adjuvant for cytotoxic T lymphocyte (CTL) induction. Groups of mice were immunized with RTS,S formulated with CpG oligonucleotide alone or in combination with aluminum hydroxide. After two immunizations spleen cells were examined for the presence of HbsAg-specific effector cells.
Table 1 : Groups of mice
Formulation
Component batches used:
Formulation process:
Formulations were prepared 3 days before each injection. All incubations were carried out at room temperature with agitation.
CpG/alum group 1 (SOOμl/dose) RTS, S (8.7μg) and gpl20 (8.7μg) were adsorbed on 100μg of Al(OH)3 or AlPO4 for 1 hour The formulation was buffered with a 10-fold concentrated PO4/NaCl pH 6.8 solution before addition of lOOμg of CpG (WD 1001). After 15 min, 50 μg/ml of fhiomersal was added as preservative.
CpG group 2 (SOOμl/dose)
RTS,S (8.7μg) and Gpl20(8.7μg) were diluted in PBS pH 6.8 before addition of lOOμg of CpG (WDIOOI). After 5 min, 50 μg/ml of thiomersal was added as preservative.
Immunological methods
Nine Balb/C mice per group received into the hind footpads 100 μl vaccine twice at a two-week-interval. Two weeks later spleen cells were harvested and used to determine the induction of HBsAg-specific CTL. For CTL analysis cells were cultured for 7 days in 6-well plates in the presence of 10 μg per ml of synthetic peptide pCMI003 corresponding to an HBsAg CTL epitope (Schirrnbeck et al. , 1995). At the end of the culture period cells were assessed in duplicate for HBsAg-specific cytolytic activity in standard [51Cr] -release assays using control and S-transfected P815 cells. Minimum and maximum release were determined with target cells without effector cells and by the addition of 3 % (v/v) Triton X-100, respectively. Results are expressed as % [5 ICr] -release (cpm of exp. culture - cpm of spont. release / cpm of max. release - cpm of spont. release).
Results
Spleen cells from both groups of mice exhibited HBsAg-specific effector cell function in 51Cr release assays (Figure 1). Untransfected P815 target cells were lysed to a much lesser degree than similar target cells expressing the HBV s gene. Lysis of the target cells diminished with decreasing effector to target cell ratios.
Conclusions
Immunization with RTS,S in combination with CpG or CpG/alum induces HBsAg- specific CTL in mice.
EVALUATION OF CPG AND CPG/ALUM IN RHESUS MONKEYS
Experiment outline
An immunogenicity study was conducted to evaluate the adjuvant effect of CpG in non-human primates. Groups of five monkeys were immunized twice with RTS,S in combination with CpG or CpG/alum. After the second immunization the immune response of the animals was assessed. Antibodies to HBsAg and lymphoproliferative as well as cytokine responses were evaluated. Table 2. Groups of monkeys
Formulation
Component batches used:
Formulation process:
Formulations were prepared one day before each injection. All incubations were carried out at room temperature with agitation.
CpG/alum group 1 (SOOμlldose)
RTS,S (50μg) was adsorbed on 500μg of Al(OH)3 for 1 hour The formulation was buffered with a 10-fold concentrated PO4/NaCl pH 6.8 solution before addition of 500μg of CpG (WDIOOI). After 15 min, 50 μg/ml of thiomersal was added as preservative. H2O+Al(OH)3+RTS,S-lH-10xPN-15m-CpG-15m-Thio
CpG group 2 (500μl/dose)
RTS,S (50μg) was diluted in PO4/NaCl buffer pH 6.8 before addition of 500μg of CpG WDIOOI . After 15 min, 50 μg/ml of thiomersal was added as preservative.
H2O +RTSS + 10xPN-15m-CpG-15m-Thio Immunological methods
Five rhesus monkeys (Macaca mulatto.) per group were immunized twice intramuscularly with 500 μl of vaccine at a four- week-interval. Sera and peripheral blood mononuclear cells (PBMC) were taken at several occasions.
HBsAg-specific antibodies in monkey sera were determined in a radio immuno assay (RIA, Abbott) according to the manufacturer's instructions.
Lymphoproliferation was assessed by using density gradient-purified PBMC from immunized rhesus monkeys. Cells were seeded in quadruplicates at 1x10s in 100 μl RPMI/5 % FCS per well in round bottom 96 well plates. Then another 100 μl of medium alone or containing soluble RTS,S (10 μg/ml) were added and parallel cultures were incubated for 48 hrs. Thereafter, 100 μl culture supernatant were replaced by fresh medium containing 1 μCi [3H]-thymidine. After 16 hrs cells were harvested onto filter plates and incorporated radioactivity was determined in a β- counter. Results are expressed in cpm and in stimulation indices (SI, = cpm antigen-containing cultures/cpm medium alone cultures), SI greater than 3 are considered as a positive response.
Flat bottom 96 well plates were prepared by coating an IFN-γ-specific capture antibody in 50 μl PBS for 4 hrs at 37 °C. The plates were washed three times and PBMC were seeded similar to lymphoproliferation assays. After 48 hrs of culture the plates were washed thrice with PBS/0.05 % Tween 20 and 50 μl of biotinylated secondary IFN-γ-specific antibody diluted in PBS/Tween/1 % FCS were added for 2 hrs. The plates were washed again and a gold-conjugated -biotin antibody was incubated for 1 hr. After additional washings the ELIspots were visualized by using a silver enhancing kit (50 μl per well). The reaction was stopped after approx. 30 min by adding deionized water. Cytokine-secreting cells were enumerated by microscopic examination. Results
Analysis of HBsAg-specific antibodies in sera of the monkeys revealed that all animals in the two groups had developed specific immune responses (Figure 2). Some responses were detectable already after one immunization. Interestingly, these responses were boosted by the second immunization only in group 1 , while titers in group 2 remained more or less constant.
Induction of specific lymphoproliferation by immunization with RTS,S in combination with CpG or CpG/alum was evaluated before immunization and 6 days post secondary immunization. All 10 animals did not exhibit any specific lymphoproliferation (SI> 3) at the study start (data not shown). In contrast, all animals in group 1 possessed strong lymphoproliferative responses 6 days post boost immunization (Figure 3). All animals from group 2 did, however, remain negative in this analysis.
The presence of RTS,S-specifιc IFN-γ-secreting cells was investigated in all monkeys before immunization and 6 days after the second dose. IFN-γ-secreting cells could not be evaluated from pre-irnmunization samples due to technical difficulties. However, such cells were detectable after secondary immunization (Figure 4). All animals in group 1 exhibited a positive response, while only one animal in group 2 was positive.
Conclusions
Immunization with RTS,S in combination with CpG induces immune responses in non-human primates. After two immunizations CpG alone induces low level HB sAg-specific antibodies, while CpG combined with alum induces high titer antibodies as well as vigorous lymphoproliferative and IFN-γ responses. Figure legends
Figure 1: CTL activity of spleen cells from immunized mice. Effector cell activity was assessed by examining 51Cr release of P815 cells (open circles) or s-transfected P815 cells (closed circles).
Figure 2: HBsAg-specific antibody responses in immunized rhesus monkeys. Specific antibodies were evaluated using a commercially available RIA. Individual values from multiple time points for each animal are shown in the table, and group averages are shown in the table and as a graphic.
Figure 3: RTS,S-specifιc lymphoproliferation in immunized rhesus monkeys 6 days post second immunization. PBMC were stimulated with RTS,S antigen and lymphoproliferative responses were measured by 3H-thymidine incorporation. Results are expressed in cpm and as SI.
Figure 4: RTS,S-specifιc IFN-γ-secreting cells from immunized rhesus monkeys. IFN-γ-secreting cells were visualized by the ELIspot method. Cytokine-secreting cells resulting in a colored spot were enumerated by microscopic examination and results are expressed semi-quantitatively (- = 0-5, 4- = 5-15, + + = 15-35, + + + = 35-50, + + + + = > 50).
References
Schirmbeck, R. , Boehm, W., Melber, K. , Reimann, J. (1995). Processing of exogenous heat-aggregated (denatured) and particulate (native) Hepatitis B surface antigen for class I-restricted epitope presentation. J. Immunol. 155:4676-4684.

Claims

Claims:
1. A vaccine formulation comprising a malaria antigen and an immunostimulatory CpG oligonucleotide.
2. A vaccine as claimed in claim 1 wherein the antigen is selected from the group, RTS, RTS*, TRAP or immunologically equivalent derivatives thereof.
3. A vaccine as claimed in claim 1 or 2 wherein the vaccine comprises TRAP or immunologically equivalent derivative and one of RTS or RTS*. 4. A vaccine formulation as claimed herein additionally comprising an aluminium salt, 3 de-O-acylated monophosphoryl lipid A or a saponin adjuvant.
5. A vaccine as claimed herein wherein the oligonucleotide comprises two CpG dinucleotides.
6. A vaccine as claimed herein wherein the CpG oligonucleotide is between 15-45 nucleotides in length.
7. A vaccine as claimed herein wherein the CpG oligonucleotide comprises at least one phosphorothioate intemucleotide bond.
8. A vaccine as claimed herein wherein the oligonucleotide is selected from the group:
Oligo (internal 5'-SEQUENCE-3' CpG Thio designation)
WD1001 TCC ATG ACG TTC CTG ACG TT + +
WD1002 TCT CCC AGC GTG CGC CAT + +
WD1003 ACC GAT AAC GTT GCC GGT GAC G + -
WD1004 G*G*G GTC AAC GTT GAG* G*G*G* G*G + Mix
WD1005 TCC ATG AGC TTC CTG AGC TT - +
WD1006 TCC ATG ACG TTC CTG ACG TT + -
WD1007 ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG + + TCG TCG TTT TGT CGT TTT GTC GTT + +
. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a vaccine of any one of claims 1 to 8 to a patient.
10. A vaccine as claimed herein for use as a medicament.
11. A method of producing a vaccine as claimed in any one of claims 1 to 8 comprising admixing a malarial antigen and a CpG immunostimulatory oligonucleotide.
12. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a CpG oligonucleotide followed after a suitable time by an effective amount of a malaria antigen.
EP00945810A 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine Ceased EP1198243A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9915204 1999-06-29
GBGB9915204.3A GB9915204D0 (en) 1999-06-29 1999-06-29 Vaccine
PCT/EP2000/005841 WO2001000231A2 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine

Publications (1)

Publication Number Publication Date
EP1198243A2 true EP1198243A2 (en) 2002-04-24

Family

ID=10856286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00945810A Ceased EP1198243A2 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine

Country Status (6)

Country Link
EP (1) EP1198243A2 (en)
AU (1) AU5977700A (en)
CA (1) CA2376926A1 (en)
GB (1) GB9915204D0 (en)
HK (1) HK1047034A1 (en)
WO (1) WO2001000231A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK1077722T3 (en) 1998-05-22 2006-11-27 Ottawa Health Research Inst Methods and products for the induction of mucosa immunity
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
WO2002058727A2 (en) * 2001-01-26 2002-08-01 Walter Reed Army Institute Of Research Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
CA2456201A1 (en) * 2001-08-10 2003-02-27 Dynavax Technologies Corporation Immunomodulatory oligonucleotide formulations and methods for use thereof
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
CN100455600C (en) * 2002-08-14 2009-01-28 阿维迪斯公司 Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
JP4199988B2 (en) * 2002-11-14 2008-12-24 大日本印刷株式会社 Decorative sheet
EP2491947A3 (en) 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010152A1 (en) * 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT772619E (en) * 1994-07-15 2006-10-31 Univ Iowa Res Found OLIGONUCLEOTIDOS IMUNOMODULADORES
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
JP2001513776A (en) * 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders
DK1005368T3 (en) * 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
EP1279401B1 (en) * 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
TR200101055T2 (en) * 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
ES2228497T3 (en) * 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. ADJUTIVE COMPOSITION INCLUDING SAPONINA AND AN IMMUNO STIMULANT OLIGONUCLEOTIDE.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010152A1 (en) * 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMSCHENETZKY M. ET AL: "SEA URCHIN ZYGOTE CHROMATIN EXHIBIT AN UNFOLDED NUCLEOSOMAL ARRAY DURING THE FIRST S PHASE", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 59, no. 2, 1 October 1995 (1995-10-01), WILEY-LISS INC, US, pages 161 - 167, XP009085011 *
NAKASHIMA A. ET AL: "INTERACTION BETWEEN POLYANIONS AND CELL NUCLEI: MECHANISM OF GELATINATION OF NUCLEI", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 228, no. 3, 21 November 1996 (1996-11-21), ACADEMIC PRESS INC. ORLANDO, FL, US, pages 846 - 851, XP001536248 *
VALDIVIA M.M ET AL: "A NOVEL CENTROMERE MONOSPECIFIC SERUM TO A HUMAN AUTOEPITOPE ON THE HISTONE H3-LIKE PROTEIN CENP-A", FEBS LETTERS, vol. 422, no. 1, 23 January 1998 (1998-01-23), ELSEVIER, AMSTERDAM, NL, pages 5 - 9, XP004261762 *

Also Published As

Publication number Publication date
WO2001000231A2 (en) 2001-01-04
GB9915204D0 (en) 1999-09-01
WO2001000231A3 (en) 2001-07-05
HK1047034A1 (en) 2003-02-07
CA2376926A1 (en) 2001-01-04
AU5977700A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
JP5108521B2 (en) Malaria primary immunization / boost vaccine
EP2277533B1 (en) Methods for vaccinating against malaria
US20060292170A1 (en) Vaccine Composition Against Malaria
US20080102091A1 (en) Vaccines
WO2007003384A1 (en) Anti-malaria vaccine
EP1198243A2 (en) Use of cpg as an adjuvant for malaria vaccine
US20060073171A1 (en) Vaccine composition against malaria
US20080131464A1 (en) Vaccines
Xiao et al. Adjuvanst and Malaria Vaccine Development
IE870684L (en) Vaccines comprising an antigen and interferon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011205

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20021129

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090418

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1047034

Country of ref document: HK